Although in the overall randomized cohort, the improvement in DFS and OS did not reach statistical significance, blinatumomab was associated with significantly improved outcomes among patients with marrow involvement, with 4-year DFS and OS 72.7% and 97.1%, respectively, for patients receiving blinatumomab (vs 53.7% and 84.8% in patients receiving chemotherapy [ P = .15 and P = .02 respectively]).
1
—
—